SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. , the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, reminds shareholders that James A. Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc., will present a corporate update from the NASDAQ Marketsite at the 2010 RedChip New York Equities Conference on March 24, 2010, at the market close (4:00 p.m. EDT). Investors are urged to listen to the live webcast at: www.redchip.com.
The Hemopurifier(R) is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Aethlon Medical, Inc.
